Aims: Cardiac troponin T (cTnT), measured with a high-sensitivity (hs) assay, is associated with cognitive decline, but the underlying mechanism is unknown. We investigated the association of hs-cTnT with cognitive function and decline, and studied whether this association was independent of cardiovascular diseases or risk factors, and N-terminal probrain natriuretic peptide (NT-proBNP). Methods and results: We studied 5407 participants (mean age 75.31 years) from the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER), who all had cardiovascular diseases or risk factors thereof. Participants with preexistent advanced clinical heart failure were excluded. Hs-cTnT and NT-proBNP obtained after 6 months of follow-up were related with cognitive function, tested repeatedly during a mean follow-up of 3.2 years. Participants with higher hs-cTnT performed worse at baseline on Stroop test (mean baseline score (standard error (SE)) lowest vs highest third 65.91 (1.16) vs 69.40 (1.10) seconds, p < 0.001), Letter-Digit Coding test (23.35 (0.32) vs 22.40 (0.31) digits coded, p < 0.001), immediate Picture-Word Learning test (9.45 (0.09) vs 9.31 (0.08) pictures remembered, p ¼ 0.002) and delayed Picture-Word Learning test (10.33 (0.12) vs 10.10 (0.12) pictures remembered, p ¼ 0.013). Furthermore, participants with higher hs-cTnT had steeper decline on Stroop test (mean annual change (SE) lowest vs highest third 0.34 (0.12) vs 1.06 (0.12) seconds, p ¼ 0.013), Letter-Digit Coding test (-0.29 (0.03) vs À0.46 (0.03) digits coded, p < 0.001), immediate Picture-Word Learning test (0.01 (0.01) vs À0.06 (0.01) pictures remembered, p < 0.001) and delayed Picture-Word Learning test (-0.03 (0.01) vs À0.12 (0.02) pictures remembered, p ¼ 0.001). Associations were independent of cardiovascular diseases risk factors or Apolipoprotein E genotype. Further adjusting for NT-proBNP levels revealed the same results. Conclusions: Higher levels of hs-cTnT associate with worse cognitive function and steeper cognitive decline in older adults independent of cardiovascular diseases, risk factors and NT-proBNP.
Introduction
Cardiac troponin T (cTnT) is a protein that is released in response to cardiomyocyte necrosis, and is routinely used in the diagnosis of acute myocardial infarction. 1 In patients with cardiovascular disease, higher levels of cTnT, measured with a high-sensitivity (hs) assay, are associated with higher risk of incident coronary heart disease, heart failure and stroke. 1, 2 Moreover, in patients free from cardiovascular disease, raised levels of hs-cTnT have also been associated with higher risk of all-cause mortality and myocardial infarction. 3 Cardiovascular diseases are important risk factors for cognitive impairment and dementia. 4 Recent evidence shows that in subjects without cardiovascular disease, higher levels of hs-cTnT are associated with silent brain infarcts and white matter lesion progression. 5 Hs-cTnT might therefore be a sensitive systemic marker for structural brain damage, which is associated with decreased cognitive function and dementia. 6 Hs-cTnT has recently also been associated with cognitive function, but the underlying mechanism is unknown. 7 Besides the fact that cardiac disease and cognitive dysfunction share common risk factors there may be an alternative explanation. Myocardial ischaemia or infarction, as detected by increased hs-cTnT, may lead to clinical heart failure or decreased cardiac function, which in turn leads to cognitive decline. 8 Given the predicted increase in prevalence of cognitive dysfunction in the coming decades, unravelling early predictors of cognitive decline is of importance. 9 The aims of this study were to investigate (a) whether subjects with higher levels of hs-cTnT are at increased risk of worse cognitive function and steeper cognitive decline; (b) whether this was independent of cardiovascular diseases or its risk factors, and (c) whether this was independent of N-terminal probrain natriuretic peptide (NT-proBNP), a marker used in the diagnosis of clinical heart failure. [10] [11] [12] We used data from the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER), which included 5804 older men and women all of whom had a cardiovascular disease or cardiovascular risk factors.
Methods

Study design and participants
Data were obtained from the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER), a randomized, double-blind, placebo-controlled trial designed to investigate the effect of pravastatin in prevention of vascular events in older individuals with preexisting cardiovascular disease or risk factors thereof. 13 Briefly, the main inclusion criteria were that participants had either pre-existing vascular disease (coronary, cerebral or peripheral) or an elevated risk of developing vascular disease because of smoking, diabetes mellitus or hypertension. Furthermore, their total cholesterol level was required to be between 4.0-9.0 mmol/l and their triglyceride concentration <6.0 mmol/l. Participants with congestive heart failure, defined as New York Heart Association functional class III or IV, were not included in the PROSPER study, nor were participants who were previously diagnosed with atrial fibrillation. 13 Furthermore, poor cognitive function at baseline, defined as a Mini-Mental Score Examination below 24 points, was an exclusion criteria. This trial included 5804 men and women aged 70-82 years old who were enrolled from three collaborating centres in Ireland, Scotland and the Netherlands. Approximately 50% of the participants had cardiovascular disease including stable angina, intermittent claudication, stroke, transient ischaemic attack, myocardial infarction and/or vascular surgery. The rest of the participants had one or more cardiovascular risk factor, defined as hypertension, smoking or diabetes mellitus. The primary outcome of the trial was the combined endpoint of definite or suspect death from coronary heart disease, non-fatal myocardial infarction and fatal or non-fatal stroke during a mean follow-up period of 3.2 years. 14 The institutional ethics committees of the three collaborating centres approved the study and all participants gave written informed consent.
cTnT and NT-proBNP measurements cTnT and NT-proBNP were measured in blood samples obtained after six months of follow-up in EDTA tubes. Both proteins were measured using an electrochemiluminiscence immunoassay on a Roche Modular Analytics E170. The Roche cTnT measurement was performed with a hs assay, which has a limit of detection of 0.003 mg/l and a 99th percentile cut-off of 0.014 mg/l. Furthermore, the Elecsys Troponin T hs assay used had a coefficient of variation of 10.38% at a cTnT concentration of 0.010 mg/l, thus the assay is able to differentiate reasonably well at lower concentrations. For those patients who had a level below the detection limit, we have assumed these values to be distributed anywhere between zero and 0.003, of which the average is 0.0015. Hs-cTnT levels below detection level were therefore set to 0.0015 mg/l in the statistical analyses. To further investigate whether the association of cTnT with cognitive function and decline was independent of clinical heart failure, we studied participants with low and high NT-proBNP levels more in detail. To be sure that participants had no clinical heart failure, we chose a conservative cut-off of 200 ng/l for NT-proBNP. Furthermore, we stratified our analyses by a less conservative cut-off of low (<400 ng/l) and high (!400 ng/l) NT-proBNP, based on relevant guidelines. 15 
Cognitive function
The mini mental state exam (MMSE) was used to evaluate global cognitive function; participants with a baseline score below 24 points were not included in PROSPER. 13 Cognitive function was tested at baseline and at 9, 18, 30 months and at the end of the study. The time-point of the measurement at the end of the study varied between 36-48 months; therefore, we performed the analysis with their individually varying time point, but report the results for the mean of these time points (at 42 months). Four different neuropsychological tests were used to assess executive function, attention, and immediate and delayed memory. The Stroop Colour-Word Test was used to test selective attention and reaction time. Participants were asked to read a colour name which was displayed in a colour different from the colour it actually names. Outcome parameter was the total number of seconds to complete the test; a higher score indicates worse performance. Processing speed was tested by the Letter-Digit Coding Test. Participants had to match certain digits with letters according to a provided key. Outcome variable was the total number of correct entries in 60 s, therefore higher scores represented better performance. The Picture-Word Learning Test was used to assess immediate and delayed memory. Fifteen pictures were presented, and participants were asked to recall as many pictures as possible in three trials. After 20 min they were asked to repeat the pictures they remembered to measure their delayed recall. Outcome parameter was the accumulated number of correct recalled pictures, immediate and after 20 min. Higher scores thus indicate better performance. A detailed description of the cognitive tests has been published previously. 16 Since treatment with pravastatin did not influence cognitive function during follow-up, we included participants from both pravastatin and placebo groups. 17 
Statistical analyses
We present our results in thirds of cTnT. Baseline characteristics of the study participants are presented as mean (standard deviation) for continuous variables and number (percentage) for categorical variables for each third of cTnT. Differences in continuous variables were tested with linear regression models; differences in categorical variables were tested by Chi-squared tests. Because of the skewed distribution of cTnT levels and log-transformed cTnT levels, all analyses were performed using the square root of cTnT, which was normally distributed (Supplementary Material, Figure 2 ). To investigate the cross-sectional association of cTnT with cognitive function, we used linear regression models. The square root levels of cTnT were included as independent variable; outcome variable was the mean baseline score on each of the four cognitive function tests. Linear mixed models were used to examine the association between cTnT and cognitive decline over time. The models included the square root of cTnT level, time (in years) and the interaction term between time and the square root of cTnT level.
We performed our analyses according to two different adjustment models. In the first model, we only adjusted for the variables age, sex, country, education, treatment with pravastatin or placebo and cognitive test version where appropriate (minimally adjusted model). In the second model, we further adjusted for apolipoprotein E (ApoE) genotype, history of cerebrovascular and cardiovascular disease, history of hypertension, history of diabetes mellitus, current smoking, baseline systolic and diastolic blood pressure, high-density lipoprotein (HDL) and low-density lipoprotein (LDL) cholesterol levels, triglycerides, body mass index and estimated glomerular filtration rate (eGFR), to investigate the potential influence of these factors on the associations. Since the observed associations did not materially differ, we chose to present the results from comprehensive adjusted models. Results from minimally adjusted models are included as supplemental material. Concerning the longitudinal analyses, we further studied the effects of potential confounders on the slope of the association by additionally including the interaction terms between time, square root of troponin level and potential confounder in the linear mixed models. These results did not materially affect the slope of the analyses and we therefore present the results of the simple models. Finally, to explore the influence of cardiovascular diseases and risk factors in more details, we performed additional analyses in which we stratified for history of cardiovascular diseases and risk factors.
To further investigate whether the association of cTnT with cognitive function and decline was independent of clinical heart failure, we stratified our analyses by low (<200 ng/l) and high (!200 ng/l) NT-proBNP level and calculated a p-value for interaction to test whether the difference was significant. In addition, we (a) further adjusted our analyses for continuous levels of NT-proBNP and (b) stratified our analyses by a less conservative cut-off of low (<400 ng/l) and high (!400 ng/l) NT-proBNP, was based on relevant guidelines. 15 Moreover, we performed additional analyses in which we excluded both participants with heart failure hospitalization during follow-up and participants who used loop diuretics at baseline, since those participants are likely to suffer from clinical heart failure. Furthermore, we performed several sensitivity analyses in which we separately excluded participants who, during follow-up, had (a) a stroke and/or transient ischaemic attack (TIA); (b) coronary events; (c) atrial fibrillation; (d) cardiovascular events; and (e) a sign of previous myocardial infarction (defined as pathological Q or QS waves on their baseline ECG). In addition, we excluded participants with high cTnT levels (defined conform 99th percentile as hs-cTnT levels >0.014 mg/l), to investigate the association of normal levels of cTnT with cognitive function and decline. Furthermore, to further investigate whether left ventricular dysfunction might have confounded our results, we adjusted our analyses for use of diuretics and angiotensin-converting enzyme (ACE) inhibitors.
Results
Out of the total number of 5804 PROSPER participants, we excluded n ¼ 397 participants with missing cTnT measurements. The final sample of the present study included n ¼ 5407 participants with a mean (standard deviation) age of 75.31 (3.36) years (Supplementary Material, Figure 1 ).
Participants with higher cTnT were older, less frequently female and had a higher prevalence of hypertension, diabetes mellitus, stroke or transient ischaemic attack, myocardial infarction and vascular disease (all p-values < 0.05) ( Table 1) . No difference in total cholesterol, HDL and LDL levels were found between the thirds of cTnT (all p-values > 0.05). Systolic and diastolic blood pressure at baseline were higher in participants with higher cTnT levels (both p-values < 0.001). Furthermore, participants with higher cTnT had a lower eGFR and higher NT-proBNP levels (both p-values < 0.001).
The association of cTnT with cognitive function at baseline and cognitive decline during follow-up is shown in Table 1 ). Figure 1 shows the results of the association of cTnT with cognitive decline, stratified by cardiovascular diseases and risk factors. Participants with a history of hypertension had a steeper decline on Letter-Digit Coding test and immediate Picture-Word Learning test (both p-values for interaction ¼ 0.011). Figure 2 shows the association of cTnT with cognitive function at baseline in participants with low (<200 ng/l) and high (!200 ng/l) NT-proBNP levels. For participants with low NT-proBNP levels, we observed that higher cTnT was associated with worse cognitive function on the Stroop test, Letter-Digit Coding test, immediate Picture-Word Learning test and delayed Picture-Word Learning test (all p-values < 0.05). Although this trend was less marked on all four cognitive function tests for participants with high NT-proBNP levels, there was no significant difference between low and high NT-proBNP levels in the association of cTnT with cognitive function (all p-values for interaction >0.05). Table 3 shows the longitudinal association of cTnT with cognitive decline in participants with low and high NT-proBNP levels. Again, a trend was found showing that in participants with low NT-proBNP levels, higher levels of cTnT were associated with steeper decline on all four cognitive function tests. This association remained significant for the immediate Picture-Word Learning test. However, this difference between low and high NT-proBNP levels in the association of cTnT with cognitive function was not significant (all p-values for interaction >0.05). When further adjusting for continuous levels of NT-proBNP and when stratifying our analyses according to the less conservative cut-off of NT-proBNP <and !400 ng/l, the association between cTnT and cognitive function and decline remained essentially the same (Supplementary Material, Tables  2 and 3 ). Furthermore, participants with a history of diabetes mellitus had a steeper decline in immediate Picture-Word learning test. In addition, the observed associations of cTnT with cognitive function and decline did not materially change when excluding participants with heart failure hospitalization during follow-up (n ¼ 205) and participants who used loop diuretics (n ¼ 588) (Supplementary Material, Table 4 ).
Furthermore, we investigated whether incident cardiovascular diseases might confound our results, by performing sensitivity analyses in which we separately excluded participants who, during follow-up, had (a) a stroke or TIA (n ¼ 378); (b) coronary events (n ¼ 575); (c) atrial fibrillation (n ¼ 507); (d) cardiovascular events (n ¼ 872); and finally (e) a sign of previous myocardial infarction (defined as pathological Q or QS-waves on their baseline ECG) (n ¼ 1211). In general, exclusion of these participants did not affect the association of cTnT with cognitive function and decline (Supplementary Material, Tables 5 and 6 ). In addition, we investigated the association of normal values of cTnT with cognitive function and decline, by excluding participants with cTnT > 0.014 mg/l, conform 99th percentile (n ¼ 1002). Results from these analyses did not essentially differ (Supplementary Material, Table 7 ). Furthermore, when we adjusted our results for use of diuretics and ACE inhibitors, our results remained broadly similar (data not shown).
Discussion
In this large prospective cohort study, we found that among 5407 older men and women, higher levels of hs-cTnT were associated with worse cognitive function at baseline and steeper cognitive decline. Results were independent of cardiovascular diseases or risk factors. Similar trends were observed in participants with lower NT-proBNP levels below levels which might be indicative of clinical heart failure. Our findings are in line with a previous study by Schneider et al., investigating the association of hs-cTnT with cognitive function. 7 This prospective follow-up study, which included 9472 communitydwelling participants with a mean age of 63 years, showed that higher levels of hs-cTnT were associated with lower scores on a digit symbol substitution test and a word fluency test, indicating worse cognitive function. Furthermore, during a median follow-up period of 13 years, higher baseline concentrations of hs-cTnT were associated with an increased risk for dementia hospitalizations. 7 Although these results did not appreciably alter when analyses were additionally adjusted for left ventricular hypertrophy and carotid intima media thickness, no information on NT-proBNP was available. In addition, this study did not consider ApoE genotype, a well-known risk factor for the development of cognitive impairment, as a potential confounder in the association between hs-cTnT and cognitive function. 18 Another difference between the present study and the study by Schneider et al. was the cognitive test battery. Both studies used measures of delayed word memory and the digit symbol substitution test, which measures processing speed and executive function. The only difference is that the atherosclerosis risk in communities study (ARIC) study used the Word Fluency Test, whereas we used the Stroop test, although both measure executive function and processing speed. We think it is unlikely that this difference in choice of tests is significant enough to make different inferences about the outcome. To our knowledge, our study is the first examining the association of hs-cTnT and cognitive function in older adults at high cardiovascular risk, which tested the potential role of cardiovascular diseases, risk factors and NT-proBNP, and adjusted for apolipoprotein E4 genotype as well.
Several mechanisms can be proposed to explain the association of cTnT with worse cognitive function and steeper cognitive decline. First, cTnT might be a reflection of underlying myocardial injury as well as cerebral damage, rather than being causally related. It is well known that cardiovascular and cerebrovascular disease share the same risk factors, including hypertension, diabetes mellitus and smoking. These risk factors for cognitive decline clearly also cause myocardial disease, resulting in increased levels of cTnT. The finding that participants with a history of hypertension and diabetes mellitus had a steeper decline on Picture-Word immediate test in stratified analyses, further supports this hypothesis. Second, although our results were found in participants without NYHA functional class stage III or IV, we do not have echocardiography data to rule out the possibility that higher levels of cTnT indicate suboptimal cardiac functioning with subsequent decreased cardiac output and cerebral hypoperfusion. 19, 20 Cerebral hypoperfusion has previously been associated with a higher risk of dementia. 21 However, this explanation is less likely since in the current study, participants with NT-proBNP levels <200 ng/l showed the same results, and additional adjustment for NT-proBNP levels did not change the results. Third, cTnT might have a direct effect in the brain, causing decreased cerebral function. However, no evidence has been provided for this explanation yet. Fourth, although it is generally believed that cTnT is only expressed in striated muscle cells, animal studies have revealed expression of troponin proteins, including troponin T, in smooth muscle cells of rats and mice as well. 22, 23 In addition, a recent report has shown the existence of cTnT in vascular smooth muscle cells of humans, and also found that cTnT contributes to calcium-mediated contraction of smooth muscle cells in mice experiments. 24 Although it has been reported that cTnT is highly specific for cardiomyocytes, these recent findings suggest that cTnT might also be a reflection of smooth muscle cell involvement. 24 Higher levels of cTnT may therefore indicate vascular smooth muscle cell damage in an early stage, before the manifestation of clinical or even subclinical diseases. This might also explain the observation that higher levels of cTnT are associated with subclinical brain disease, including silent brain infarcts and white matter hyperintensities. 5 Speculatively, cTnT is not only released by cardiomyocytes but also by smooth muscle cells in the brain vasculature, and may therefore mark structural brain damage as a cause of cognitive decline.
The magnitude of the association between cTnT and cognitive decline that we report, is comparable in magnitude to associations of known risk factors of cognitive decline, such as ApoE4 carriership, smoking status and history of diabetes, indicating that the effects are clinically relevant.
A first limitation of this study might be that all participants had cardiovascular diseases or risk factors thereof, which might restrict the extrapolation of our findings to a general population of older individuals. However, at the same time this is an advantage of our study, since it allows us to perform several sensitivity analyses to investigate the influence of cardiovascular diseases and risk factors on the association between cTnT and cognitive function. Second, although we adjusted our analyses for potential confounders, it is uncertain if this fully accounts for the differences between the troponin groups. In addition, there might still be other factors which we did not consider in our analyses. Furthermore, the lack of extensive information on cardiac functioning is a weakness of our study. A strength of this study is the large sample size of 5407 participants, all of whom underwent repeated extensive neuropsychological examination including four different cognitive function tests, during a mean follow-up period of 3.2 years, and, critically, inclusion and adjustment for NT-proBNP measures. Furthermore, cTnT measurements were performed using a high-sensitivity assay, which can detect 10-fold lower concentrations than the usual assay, and therefore allows detection of already very minor damage of the myocardial tissue.
Higher levels of hs-cTnT associate with worse cognitive function and steeper cognitive decline in older adults independent of cardiovascular diseases and risk factors and NT-proBNP. Adjusted p-values were calculated using the interaction term of time Â square root of troponin levels. Adjusted for age, sex, country, education, treatment with pravastatin or placebo, test version for LDCT and PLT, ApoE genotype, history of cerebrovascular and cardiovascular disease, history of hypertension, history of diabetes mellitus, current smoking, baseline systolic and diastolic blood pressure, high-density lipoprotein (HDL) and low-density lipoprotein (LDL) cholesterol, triglycerides, body mass index and estimated glomerular filtration rate (eGFR).
